Morgan Stanley analyst Robert Davies lowered the firm’s price target on Medacta Group to CHF 107 from CHF 109 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly